Vyome price to sales ratio HIND

Market value divided by revenue over the last twelve months, since 2017.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 3.4×; May 2026
10-year median: 0.3×
10-year range: 0.0× to 20.2×
Peer median: 0.9×

Vyome's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in May 2026, at 3.4×.

On the days it had one over the last ten years, its median was 0.3×, from 0.0× in Jan 2018 to 20.2× in Jan 2021.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.4×	2.6×	4.8×
2025	5.0×	0.0×	7.0×
2024	0.4×	0.2×	0.7×
2023	0.3×	0.1×	0.7×
2022	0.3×	0.3×	1.3×
2021	9.5×	4.9×	20.2×
2020	5.0×	0.0×	5.6×
2019	0.0×	0.0×	0.0×
2018	0.0×	0.0×	0.0×
2017	0.0×	0.0×	0.0×

Against its peers

Companies in Drug Manufacturers - General nearest Vyome's size, closest first, today.

Company	Price to sales ratio
HINDVyome	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
Peer median	0.9×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Vyome

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.